BonesLabsBlog
Back to all posts
Uncategorized

Pinealon

Pinealon: A Khavinson Tripeptide Bioregulator Studied for Neuroprotection

Research summary. Pinealon is a synthetic tripeptide (Glu-Asp-Arg) belonging to the Khavinson "peptide bioregulator" family developed at the St. Petersburg Institute of Bioregulation and Gerontology. The proposed mechanism — direct interaction with chromatin and gene-expression modulation rather than canonical receptor binding — is unusual relative to most peptide pharmacology. Reported preclinical effects centre on neuronal protection against hypoxic and oxidative stress and on cognitive endpoints in rodent ageing models. The published evidence base is dominated by a single research programme.

Molecular profile

  • Sequence: Glu-Asp-Arg (EDR)
  • Molecular formula: C₁₅H₂₆N₆O₈
  • Molecular weight: ~418.4 g/mol
  • PubChem CID: 18220191
  • CAS number: 3031-94-5
  • Synonyms: Glutamyl-aspartyl-arginine, T-33 peptide

Mechanism of action

Pinealon is reported to act through a non-classical mechanism. Unlike most peptides, it has not been shown to engage cell-surface or cytoplasmic receptors. The Khavinson group has reported that very short peptides of this class are small enough to traverse plasma and nuclear membranes, where they are proposed to interact with chromatin and modulate gene-expression patterns. Cell-culture work in HeLa cells has reported nuclear localisation of Pinealon and changes in heterochromatin condensation consistent with epigenetic-level modulation.

This proposed mechanism is the central claim of the bioregulator hypothesis, and it remains debated. Independent biochemical characterisation of direct DNA or chromatin binding is limited.

Preclinical research highlights

Hypoxia and oxidative-stress protection. Rodent and cell-culture work has reported that Pinealon administration reduces neuronal apoptosis under hypoxic conditions and lowers reactive-oxygen-species accumulation in cortical neurons. Effects have been described in primary neuronal cultures and in whole-animal hypoxia models.

Cognitive endpoints in ageing rodents. Maze-learning and memory-task research in aged rats has reported that Pinealon administration is associated with improved performance relative to vehicle controls, with the effect interpreted as reflecting reduced age-related neuronal loss.

Circadian and pineal-axis effects. Some published work has reported effects on melatonin synthesis and circadian-related gene expression, though this literature is modest in size.

Heterochromatin decondensation. A characteristic finding reported across the Khavinson tripeptide family — including Pinealon — is decondensation of heterochromatin in lymphocytes and other cell types from aged donors, interpreted as reactivation of age-silenced gene loci.

Limitations of the evidence base

The Pinealon literature shares the limitations common to the Khavinson bioregulator family:

  • Most published studies originate from a single research programme, limiting independent replication.
  • The proposed direct-DNA-interaction mechanism has not been firmly established by independent biochemical work outside the originating group.
  • Western pharmacology and gerontology literature contains comparatively little independent validation of these tripeptides.
  • Reported effect sizes vary widely across studies, and dosing protocols are heterogeneous.

Researchers working with Pinealon should treat the existing literature as hypothesis-generating rather than confirmatory.

Current research status

Pinealon is an investigational research peptide. It is not approved by the FDA for any indication. Outside Russia, it is not in late-stage clinical development in any major Western trial registry.

For research-supplier contexts, Pinealon is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

  • Pinealon is a Khavinson-family tripeptide (Glu-Asp-Arg) studied predominantly for neuroprotection and cognitive endpoints in rodent ageing models.
  • The proposed mechanism — direct chromatin interaction and gene-expression modulation — is unusual and not yet independently established in the broader pharmacology literature.
  • Reported preclinical effects include hypoxic-neuronal protection, antioxidant action in cortical neurons, and improved performance on rodent cognitive tasks.
  • The literature is dominated by a single research programme; independent replication is limited.
  • Pinealon is not an FDA-approved drug.

References

  1. Khavinson VK, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Bull Exp Biol Med. 2014;156(5):635–639.
  2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

This article is provided for educational and research purposes only. Pinealon is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.